Triethylenemelamine |
|
| ATC code | |
|---|
|
2,4,6-Tris(aziridin-1-yl)-1,3,5-triazine
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
| ECHA InfoCard | 100.000.076 |
|---|
|
| Formula | C9H12N6 |
|---|
| Molar mass | 204.237 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
C1CN1c2nc(nc(n2)N3CC3)N4CC4
|
InChI=1S/C9H12N6/c1-2-13(1)7-10-8(14-3-4-14)12-9(11-7)15-5-6-15/h1-6H2 NKey:IUCJMVBFZDHPDX-UHFFFAOYSA-N N
|
N Y (what is this?) (verify) |
Triethylenemelamine (abbreviated TEM, also called Tretamine) is a drug used in chemotherapy.[1]
It can cause chromatid aberrations in cell models.[2]
See also
References
Intracellular chemotherapeutic agents / antineoplastic agents (L01) |
|---|
SPs/MIs (M phase) | | Block microtubule assembly | |
|---|
| Block microtubule disassembly |
- Taxanes (Cabazitaxel
- Docetaxel#
- Larotaxel
- Ortataxel†
- Paclitaxel#
- Tesetaxel)
- Epothilones (Ixabepilone)
|
|---|
|
|---|
DNA replication inhibitor | DNA precursors/ antimetabolites (S phase) | | Folic acid | |
|---|
| Purine | |
|---|
| Pyrimidine |
- DNA polymerase inhibitor (Cytarabine# +daunorubicin)
|
|---|
| Deoxyribonucleotide | |
|---|
|
|---|
Topoisomerase inhibitors (S phase) | | I |
- Camptotheca (Belotecan
- Camptothecin
- Cositecan†
- Etirinotecan pegol†
- Exatecan
- Gimatecan
- Irinotecan#
- Lurtotecan‡
- Rubitecan‡
- Silatecan§
- Topotecan)
|
|---|
| II | |
|---|
| II+Intercalation | |
|---|
|
|---|
Crosslinking of DNA (CCNS) | | Alkylating | |
|---|
| Platinum-based | |
|---|
| Nonclassical | |
|---|
| Intercalation | |
|---|
|
|---|
|
|---|
| Photosensitizers/PDT | |
|---|
| Other | | Enzyme inhibitors |
- FI (Tipifarnib§)
- CDK inhibitors (Abemaciclib
- Alvocidib†
- Palbociclib
- Ribociclib
- Seliciclib†)
- PrI
- PhI (Anagrelide)
- IMPDI (Tiazofurin§)
- LI (Masoprocol)
- PARP inhibitor (Fuzuloparib
- Niraparib +abiraterone acetate
- Olaparib
- Rucaparib)
- HDAC (Belinostat
- Entinostat
- Panobinostat
- Romidepsin
- Vorinostat)
- PIKI (Pi3K) (Alpelisib
- Copanlisib‡
- Duvelisib
- Idelalisib
- Inavolisib
- Umbralisib‡)
- IDH (Enasidenib
- Ivosidenib
- Olutasidenib
- Vorasidenib)
|
|---|
| Receptor antagonists | |
|---|
| Other/ungrouped |
- Adagrasib
- Aflibercept
- Arsenic trioxide# (Realgar/Indigo naturalis#)
- Asparagine depleters (Asparaginase#/Pegaspargase)
- Axicabtagene ciloleucel
- Belzutifan
- Bexarotene
- Brexucabtagene autoleucel
- Calaspargase pegol
- Celecoxib
- Ciltacabtagene autoleucel
- Darinaparsin
- Demecolcine
- Denileukin diftitox
- Eflornithine
- Elesclomol§
- Elsamitrucin
- Epacadostat
- Eribulin
- Estramustine
- Glasdegib
- Idecabtagene vicleucel
- Idroxioleic acid
- Imetelstat
- Lifileucel
- Lisocabtagene maraleucel
- Lonidamine
- Lucanthone
- Lurbinectedin
- Mitoguazone
- Mitotane
- Nadofaragene firadenovec
- Navitoclax
- Nirogacestat
- Obecabtagene autoleucel
- Oblimersen†
- Omacetaxine mepesuccinate
- Para-toluenesulfonamide
- Pelabresib
- Plitidepsin
- Retinoids (Alitretinoin
- Tretinoin#)
- Selinexor
- Sitimagene ceradenovec
- Sotorasib
- Tabelecleucel
- Tagraxofusp
- Talimogene laherparepvec
- Tazemetostat
- Tebentafusp
- Tiazofurine
- Tigilanol tiglate
- Tisagenlecleucel
- Trabectedin
- Veliparib
- Venetoclax
- Verdinexor
- Vosaroxin
|
|---|
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|